NOG Antikörper (AA 156-170)

Produktnummer ABIN1737419

Der Kaninchen Polyklonal Anti-NOG-Antikörper wurde für WB validiert. Er ist geeignet, NOG in Proben von Human, Maus und Ratte zu detektieren.

Kurzübersicht für NOG Antikörper (AA 156-170) (ABIN1737419)

Target: NOG (Noggin (NOG))

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser NOG Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-NOG Antikörper

Bindungsspezifität: AA 156-170

Spezifität: Reacts with Noggin from human, mouse and rat

Aufreinigung: Antigen affinity purified

Immunogen: Synthetic peptide comprising residues 156-170 [PVLYAWNDLGSRFWP] of the human Noggin protein

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise:

Working dilution: Optimal dilution should be determined by the end user.
The following are guidelines only:
- WB : 1/1 000 to 1/2 000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS, Sodium azide 0.02 %

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Short term storage at +4°C. For extended periods store in aliquots at -20°C. Antibodies are guaranteed for 6 month from date of receipt.

Haltbarkeit: 6 months

Details zu NOG

Target: NOG (Noggin (NOG))

Andere Bezeichnung: Noggin

Hintergrund: Noggin is involved in numerous developmental processes, such as neural tube fusion and joint formation. The morphogenesis of organs is initiated by a downgrowth from a layer of epithelial stem cells. This process is achieved through the receipt of signals from 1) a WNT protein (WNT3A) to stabilize beta-catenin, and 2) Noggin, which is a bone morphogenetic protein inhibitor.Noggin mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) have been identified, which have multiple joint fusion as their principal defect.

Pathways: Stem Cell Maintenance, Tube Formation